Baird downgraded Frequency Therapeutics to Neutral from Outperform with a price target of 50c, down from $4. The all-stock merger transaction with Korro Bio expected to close in the fourth quarter of this year, the analyst tells investors in a research note. The firm downgraded Frequency ahead of the closure of the transaction.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FREQ:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue